Evidence map›Paper›PMID 32103097›Full record

ArticleScientific reports2020

Complete Protection in Macaques Conferred by Purified Inactivated Zika Vaccine: Defining a Correlate of Protection.

Ginger Young, Kelly J Bohning, Melissa Zahralban-Steele, Greg Hather, Sambasivarao Tadepalli, Kristen Mickey, C Steven Godin, Srisowmya Sanisetty, Stephanie Sonnberg, Hetal K Patel and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. An Overview of Zika Virus and Zika Virus Induced Neuropathies.International journal of molecular sciences · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Ginger YoungTakeda Vaccines, Inc., Cambridge, MA, USA. ginger.young@takeda.com.
Kelly J BohningTakeda Vaccines, Inc., Cambridge, MA, USA.
Melissa Zahralban-SteeleTakeda Vaccines, Inc., Cambridge, MA, USA.
Greg HatherTakeda Pharmaceuticals, Inc., Cambridge, MA, USA.
Sambasivarao TadepalliCharles River Laboratories, Mattawan, MI, USA.
Kristen MickeyViracor Eurofins Lee's Summit, Missouri, MO, USA.
C Steven GodinInotiv, Gaithersburg, MD, USA.
Srisowmya SanisettyTakeda Vaccines, Inc., Cambridge, MA, USA.
Stephanie SonnbergTakeda Vaccines, Inc., Cambridge, MA, USA.
Hetal K PatelTakeda Vaccines, Inc., Cambridge, MA, USA.
Hansi J DeanTakeda Vaccines, Inc., Cambridge, MA, USA.
Takeda (United States) · USCharles River Laboratories (United States) · USEurofins (United States) · US

Funding

Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority HHSO100201600015C
6 · The paper itself

Abstract

A critical global health need exists for a Zika vaccine capable of mitigating the effects of future Zika epidemics. In this study we evaluated the antibody responses and efficacy of an aluminum hydroxide adjuvanted purified inactivated Zika vaccine (PIZV) against challenge with Zika virus (ZIKV) strain PRVABC59. Indian rhesus macaques received two doses of PIZV at varying concentrations ranging from 0.016 µg - 10 µg and were subsequently challenged with ZIKV six weeks or one year following the second immunization. PIZV induced a dose-dependent immune response that was boosted by a second immunization. Complete protection against ZIKV infection was achieved with the higher PIZV doses of 0.4 µg, 2 µg, and 10 µg at 6 weeks and  with 10 ug PIZV at  1 year following vaccination. Partial protection was achieved with the lower PIZV doses of 0.016 µg and 0.08 µg. Based on these data, a neutralizing antibody response above 3.02 log

Indexed as

Vaccines, InactivatedViral VaccinesZika VirusZika Virus InfectionAnimalsAntibodies, NeutralizingDisease Models, AnimalFemaleImmunoglobulin GMacacaMaleRNA, ViralVaccinationAntibodies, NeutralizingImmunoglobulin GRNA, ViralVaccines, InactivatedViral Vaccines

Identifiers

PMID32103097
PMCPMC7044319
OpenAlexW3007304429

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.